Clinical trials: Central Nervous System Neoplasms
Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs)
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
The goal of this observational study is to validate the EQ-5D-Y-3L and EQ-5D-Y-5L in measuring health-related quality of life (HRQoL) for paediatric patients with different health conditions in China.
- Conditions
- Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
- Trial name
- NCT06873672
- Where
- China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Brain Metastases
GliaSite 1-3 Mets Study
This study has been designed to compile information on the efficacy of the GliaSite RTS combined with radiosurgery in the treatment of newly diagnosed metastatic brain tumors.
- Trial name
- NCT00589212
- Testing
- GliaSite Radiation Therapy System
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Hologic, Inc.
Melanoma, Glioma
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors.
- Conditions
- Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT05538130
- Testing
- PF-07799544, PF-07799933
- Where
- 66 sites in United States, Australia and 5 more
- Volunteers
- 148 people
- Sponsor
- Pfizer
Brain Neoplasm, Primary, Brain Neoplasms, Malignant
Risk Factors for Adult-Onset Brain Tumors
Study Objective: Brain tumors are poorly understood. The purpose of this research is to examine whether factors in lifestyle play a role in brain tumor development.
- Conditions
- Brain Neoplasm, Primary, Brain Neoplasms, Malignant, Brain Neoplasms, Benign
- Trial name
- NCT00592865
- Where
- 5 sites in United States
- Volunteers
- 850 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer
Evaluation of the Efficacy and Safety of Befotertinib Combined With Bevacizumab as First-Line Treatment for EGFR-Positive Non-Small Cell Lung Cancer With Brain Metastases: A Single-Arm, Open-Label, Prospective Phase II Clinical Study
This study evaluates the safety and efficacy of Befotertinib combined with Bevacizumab as a first-line treatment for patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC) accompanied by brain or…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), EGFR Mutation-Positive Lung Cancer, Brain Metastases, Leptomeningeal Metastases
- Trial name
- Better Brain (NCT06728865)
- Testing
- The treatment regimen is Befotertinib combined with Bevacizumab.
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Li-kun Chen
Brain Metastases, Diffuse Gliomas
Preclinical Brain Tumor Models
Background: Primary or secondary brain tumors (metastases) remain associated with a very poor prognosis linked to significant therapeutic resistance.
- Trial name
- HITCH (NCT06045065)
- Testing
- Fresh tumor sampling
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Brain Metastases
Improving Therapeutic Ratio With Hypo Fractionated Stereotactic Radiotherapy for Brain Metastases
Randomized phase II trial. The study aims to investigate a different and potentially safer radio therapeutic treatment method for brain metastases.
- Trial name
- SAFESTEREO (NCT05346367)
- Testing
- SRT, fSRT
- Where
- Netherlands
- Volunteers
- 130 people
- Sponsor
- Haaglanden Medical Centre
High Grade Meningioma
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
This research study is studying a drug as a possible treatment for High Grade Meningioma. The drug involved in this study is an immunotherapy drug called pembrolizumab
- Trial name
- NCT03279692
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Massachusetts General Hospital
Brain Neoplasms, Neoplasm Metastasis
A Trial of Postoperative Whole Brain Radiation Therapy vs. Salvage Stereotactic Radiosurgery Therapy for Metastasis
The aim of this study is to evaluate non-inferiority of salvage stereotactic radiosurgery (SRS) in the patients who received surgical resection for brain metastases in comparison with postoperative whole brain radiation therapy…
- Trial name
- NCT00280475
- Testing
- Whole brain radiation therapy arm, Salvage stereotactic radiosurgery arm
- Where
- 21 sites in Japan
- Volunteers
- 270 people
- Sponsor
- Haruhiko Fukuda
Brain and Central Nervous System Tumors
Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00003375
- Testing
- lomustine, procarbazine hydrochloride, vincristine sulfate
- Volunteers
- 370 people
- Sponsor
- Radiation Therapy Oncology Group
Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and…
- Conditions
- Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm
- Trial name
- NCT02359565
- Testing
- Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging
- Where
- 12 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- National Cancer Institute (NCI)
Brain Neoplasms
Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS
In this research study the investigators want to learn more about the quality of life before, during and after cancer treatment in patients with central nervous system brain tumors.
- Trial name
- PROMIS-QOL (NCT02603692)
- Testing
- PROMIS-QOL
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Non-Small Cell Lung Cancer, Brain Metastases
Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)
1. Compare the effect and safety of gefitinib alone with gefitinib plus concomitant WBRT(whole-brain radiotherapy ) in treatment of NSCLC patients harboring an EGFR mutation with multiple BM. 2.
- Conditions
- Non-Small Cell Lung Cancer, Brain Metastases, EGFR Gene Mutation
- Trial name
- EGFR (NCT02338011)
- Testing
- Gefitinib, WBRT
- Where
- China
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Shanghai Chest Hospital
Primary Brain Tumor
Neurocognitive Function After Proton Therapy in Children and Adolescents
Brain tumors are the second most frequent malignant diseases in children and adolescents. In the study the short and medium term consequences of proton therapy on cognitive processes in particular on executive functions in…
- Trial name
- ELBE-ProKids (NCT04066465)
- Where
- 3 sites in Germany
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Technische Universität Dresden
EGFR Activating Mutation, Leptomeningeal Metastasis
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
Leptomeningeal disease is malignant seeding of the leptomeninges and presents with a variety of symptoms frequently impacting quality of life.
- Conditions
- EGFR Activating Mutation, Leptomeningeal Metastasis, Non Small Cell Lung Cancer
- Trial name
- NCT05257967
- Testing
- Lumbar puncture and Phlebotomy
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- British Columbia Cancer Agency
Short Time Examination, Brain Metastases
Early [18F]-FDG PET Dynamic Analysis in Brain Metastases After Radiotherapy.
Various treatment options are available for brain metastases, depending on factors such as lesion site or number lesions. Radiotherapy is a commonly used treatment.
- Conditions
- Short Time Examination, Brain Metastases, Radiation Necrosis
- Trial name
- DYNFDGTEP (NCT07632092)
- Testing
- CT scan
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Neoplasm Metastases
Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302)
The aim of the study is to assess prospectively the impact of radiosurgery on the quality of life in patients with brain metastases.
- Trial name
- PRAMECE (NCT02565433)
- Testing
- questionnaire administration
- Where
- France
- Volunteers
- 52 people
- Sponsor
- Centre Oscar Lambret
Social Behaviour, Brain Neoplasms
Social Cognition in Children Treated for a Brain Tumour
There is ample evidence that children treated for a brain tumour (BT) often develop deficits in social and emotional functioning. The investigators wish to examine the cause of these deficits, i.e.
- Conditions
- Social Behaviour, Brain Neoplasms, Cystic Fibrosis
- Trial name
- NCT01599052
- Where
- 4 sites in Belgium, Netherlands
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Cushing's Syndrome, Pituitary Adenoma
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
Lentiginosis refers to groups of diseases marked by the presence of pigmented spots on the skin. These conditions are most commonly associated with multiple tumors and changes in hormone producing glands.
- Conditions
- Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease
- Trial name
- NCT00001452
- Testing
- oCRH
- Where
- United States
- Volunteers
- 1,387 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Brain and Central Nervous System Tumors
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors
RATIONALE: Monoclonal antibodies can locate tumor cells and deliver radioactive tumor-killing substances such as radioactive iodine to them without harming normal cells.
- Trial name
- NCT00003478
- Testing
- conventional surgery, iodine I 131 monoclonal antibody 81C6, radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Duke University